Terms: = Gastric cancer AND CgA AND Treatment
43 results:
1. Clinicopathological features and differential diagnosis of gastric metastases.
Chen W; Liu C; Liu Y; Yuan J; Wang Z
World J Surg Oncol; 2023 Aug; 21(1):258. PubMed ID: 37608278
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.
Wang Y; Wei X; Ke B; Liu J; Guo Y; Liu Y; Chen Y; Ding T; Wang Y; Meng B; Sun B; Zang F
Histopathology; 2023 Oct; 83(4):631-646. PubMed ID: 37356975
[TBL] [Abstract] [Full Text] [Related]
3. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
4. Chromogranin B in blood serum of patients with neuroendocrine tumors.
Lyubimova NV; Timofeev YS; Markovich AA; Lebedeva AV; Karamisheva EI; Delektorskaya VV; Kushlinskii NE
Klin Lab Diagn; 2022 Aug; 67(8):440-443. PubMed ID: 36095079
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.
Lu J; Jin M; Zhou X; Chen X; Shao Y; Jiang X
APMIS; 2022 Mar; 130(3):169-180. PubMed ID: 34862662
[TBL] [Abstract] [Full Text] [Related]
6. Anticancer Effects of the
Tosoc JPS; Nuñeza OM; Sudha T; Darwish NHE; Mousa SA
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641577
[No Abstract] [Full Text] [Related]
7. Is Additional Gastrectomy Required for Elderly Patients after Endoscopic Submucosal Dissection with Endoscopic Curability C-2 for Early gastric cancer?
Hatta W; Gotoda T; Koike T; Uno K; Asano N; Imatani A; Masamune A
Digestion; 2022; 103(1):83-91. PubMed ID: 34638125
[TBL] [Abstract] [Full Text] [Related]
8. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract] [Full Text] [Related]
9. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract] [Full Text] [Related]
10. Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach.
Wang N; Kong R; Han W; Lu J
Curr Mol Med; 2021; 21(8):655-664. PubMed ID: 32442081
[TBL] [Abstract] [Full Text] [Related]
11. [Research advance in gastric neuroendocrine tumors].
Wang Z; Gu Y; Ren Y; Wang K; Ma Z; Jiao Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Jan; 44(1):92-99. PubMed ID: 30837409
[TBL] [Abstract] [Full Text] [Related]
12. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
[TBL] [Abstract] [Full Text] [Related]
13. Α-fetoprotein producing hepatoid gastric adenocarcinoma with neuroendocrine differentiation: A case report.
Li T; Liu T; Wang M; Zhang M
Medicine (Baltimore); 2018 Sep; 97(37):e12359. PubMed ID: 30212993
[TBL] [Abstract] [Full Text] [Related]
14. Metastatic neuroendocrine pancreatic tumor - Case report.
Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C
J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066
[No Abstract] [Full Text] [Related]
15. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract] [Full Text] [Related]
16. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract] [Full Text] [Related]
17. Multivariate analysis of metastasis‑related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features.
Tang C; Gong L; Zou W; Zhang J; Zhou Y; Wu X; Lu F; Ouyang C; Liu X
Oncol Rep; 2016 Dec; 36(6):3343-3352. PubMed ID: 27748940
[TBL] [Abstract] [Full Text] [Related]
18. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract] [Full Text] [Related]
19. CEA Level, Radical Surgery, CD56 and cga Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.
Li Y; Bi X; Zhao J; Huang Z; Zhou J; Li Z; Zhang Y; Li M; Chen X; Hu X; Chi Y; Zhao D; Zhao H; Cai J
Medicine (Baltimore); 2016 May; 95(18):e3567. PubMed ID: 27149478
[TBL] [Abstract] [Full Text] [Related]
20. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract] [Full Text] [Related]
[Next]
